Cargando…
A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity
In this study, a strategy based on polymeric immunoglobulin G scaffolds (PIGS) was used to produce a vaccine candidate for Mycobacterium tuberculosis. A genetic fusion construct comprising genes encoding the mycobacterial Ag85B antigen, an immunoglobulin γ‐chain fragment and the tailpiece from immun...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230950/ https://www.ncbi.nlm.nih.gov/pubmed/29682888 http://dx.doi.org/10.1111/pbi.12932 |
_version_ | 1783370145541914624 |
---|---|
author | Webster, Gina R. van Dolleweerd, Craig Guerra, Thais Stelter, Szymon Hofmann, Sven Kim, Mi‐Young Teh, Audrey Y‐H. Diogo, Gil Reynolds Copland, Alastair Paul, Mathew J. Hart, Peter Reljic, Rajko Ma, Julian K‐C. |
author_facet | Webster, Gina R. van Dolleweerd, Craig Guerra, Thais Stelter, Szymon Hofmann, Sven Kim, Mi‐Young Teh, Audrey Y‐H. Diogo, Gil Reynolds Copland, Alastair Paul, Mathew J. Hart, Peter Reljic, Rajko Ma, Julian K‐C. |
author_sort | Webster, Gina R. |
collection | PubMed |
description | In this study, a strategy based on polymeric immunoglobulin G scaffolds (PIGS) was used to produce a vaccine candidate for Mycobacterium tuberculosis. A genetic fusion construct comprising genes encoding the mycobacterial Ag85B antigen, an immunoglobulin γ‐chain fragment and the tailpiece from immunoglobulin μ chain was engineered. Expression was attempted in Chinese Hamster Ovary (CHO) cells and in Nicotiana benthamiana. The recombinant protein assembled into polymeric structures (TB‐PIGS) in N. benthamiana, similar in size to polymeric IgM. These complexes were subsequently shown to bind to the complement protein C1q and FcγRs with increased affinity. Modification of the N‐glycans linked to TB‐PIGS by removal of xylose and fucose residues that are normally found in plant glycosylated proteins also resulted in increased affinity for low‐affinity FcγRs. Immunization studies in mice indicated that TB‐PIGS are highly immunogenic with and without adjuvant. However, they did not improve protective efficacy in mice against challenge with M. tuberculosis compared to conventional vaccination with BCG, suggesting that additional or alternative antigens may be needed to protect against this disease. Nevertheless, these results establish a novel platform for producing polymeric antigen‐IgG γ‐chain molecules with inherent functional characteristics that are desirable in vaccines. |
format | Online Article Text |
id | pubmed-6230950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62309502018-11-20 A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity Webster, Gina R. van Dolleweerd, Craig Guerra, Thais Stelter, Szymon Hofmann, Sven Kim, Mi‐Young Teh, Audrey Y‐H. Diogo, Gil Reynolds Copland, Alastair Paul, Mathew J. Hart, Peter Reljic, Rajko Ma, Julian K‐C. Plant Biotechnol J Research Articles In this study, a strategy based on polymeric immunoglobulin G scaffolds (PIGS) was used to produce a vaccine candidate for Mycobacterium tuberculosis. A genetic fusion construct comprising genes encoding the mycobacterial Ag85B antigen, an immunoglobulin γ‐chain fragment and the tailpiece from immunoglobulin μ chain was engineered. Expression was attempted in Chinese Hamster Ovary (CHO) cells and in Nicotiana benthamiana. The recombinant protein assembled into polymeric structures (TB‐PIGS) in N. benthamiana, similar in size to polymeric IgM. These complexes were subsequently shown to bind to the complement protein C1q and FcγRs with increased affinity. Modification of the N‐glycans linked to TB‐PIGS by removal of xylose and fucose residues that are normally found in plant glycosylated proteins also resulted in increased affinity for low‐affinity FcγRs. Immunization studies in mice indicated that TB‐PIGS are highly immunogenic with and without adjuvant. However, they did not improve protective efficacy in mice against challenge with M. tuberculosis compared to conventional vaccination with BCG, suggesting that additional or alternative antigens may be needed to protect against this disease. Nevertheless, these results establish a novel platform for producing polymeric antigen‐IgG γ‐chain molecules with inherent functional characteristics that are desirable in vaccines. John Wiley and Sons Inc. 2018-07-21 2018-12 /pmc/articles/PMC6230950/ /pubmed/29682888 http://dx.doi.org/10.1111/pbi.12932 Text en © 2018 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Webster, Gina R. van Dolleweerd, Craig Guerra, Thais Stelter, Szymon Hofmann, Sven Kim, Mi‐Young Teh, Audrey Y‐H. Diogo, Gil Reynolds Copland, Alastair Paul, Mathew J. Hart, Peter Reljic, Rajko Ma, Julian K‐C. A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
title | A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
title_full | A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
title_fullStr | A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
title_full_unstemmed | A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
title_short | A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
title_sort | polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230950/ https://www.ncbi.nlm.nih.gov/pubmed/29682888 http://dx.doi.org/10.1111/pbi.12932 |
work_keys_str_mv | AT websterginar apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT vandolleweerdcraig apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT guerrathais apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT stelterszymon apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT hofmannsven apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT kimmiyoung apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT tehaudreyyh apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT diogogilreynolds apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT coplandalastair apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT paulmathewj apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT hartpeter apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT reljicrajko apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT majuliankc apolymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT websterginar polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT vandolleweerdcraig polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT guerrathais polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT stelterszymon polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT hofmannsven polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT kimmiyoung polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT tehaudreyyh polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT diogogilreynolds polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT coplandalastair polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT paulmathewj polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT hartpeter polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT reljicrajko polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity AT majuliankc polymericimmunoglobulinantigenfusionproteinstrategyforenhancingvaccineimmunogenicity |